Our Commitment to R&D Collaboration
- Building Value
At OncoMark, we are committed to building value through partnering via:
- Actively pursuing new licensing opportunities in cancer biomarkers.
- Biomarker validation for predictive applications, e.g. drug development.
- Biomarker validation for prognostic aplication.
- Finding suitable partners for our R&D projects.
- Co-operating with commercially well-established local partners in the countries where we do not have a direct presence.
- Sharing risk and reward for new product development.
What are our strengths and what do we offer?
- Proven R&D experience particularly devoted to cancer molecular diagnostics using tissue-based approaches.
- Proprietary research validated technology platforms for IHC quantitation & interpretation.
- Excellent know-how and resources for biomarker discovery, validation and assay development.
- Expert partners for EU projects.